Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories (NYSE: ABT) generates a steady flow of news across diagnostics, medical devices, nutritionals and branded generic medicines, reflecting its role as a global healthcare company serving people in more than 160 countries. News coverage on this page highlights regulatory milestones, product launches, clinical data, corporate actions and community initiatives that shape Abbott’s business and its impact on patients.
Recent announcements include FDA approvals and clearances for cardiovascular and structural heart technologies, such as the Volt PFA System for treating atrial fibrillation and the Amplatzer Piccolo Delivery System for minimally invasive closure of patent ductus arteriosus in premature infants. Abbott also reports developments in diabetes care and metabolic health, including enhancements to its Libre app through the Libre Assist feature, which uses generative AI and continuous glucose monitoring data to help people living with diabetes understand how food choices may affect glucose levels, and the expansion of its Lingo over-the-counter continuous glucose monitor to additional mobile platforms.
Investors and observers will also find news about Abbott’s nutrition business, such as new Ensure Max Protein shakes aimed at supporting muscle health for active and older adults, as well as information on public health partnerships and community programs like the "We Give Blood" competition with the Big Ten Conference and the HeartMates community for people with heart health challenges. Corporate updates include dividend declarations and increases, as well as the announced Agreement and Plan of Merger to acquire Exact Sciences Corporation, which would expand Abbott’s presence in cancer screening and precision oncology diagnostics.
This news feed provides a centralized view of Abbott’s latest announcements, allowing readers to follow developments in its key business segments and understand how new products, regulatory events and strategic transactions may influence the company over time.
Abbott (NYSE:ABT) and the Big Ten Conference have launched 'The We Give Blood Drive,' a first-ever conference-wide blood donation competition. Running from Sept. 26 through Dec. 6, the initiative aims to address critical U.S. blood shortages by engaging 18 member schools' students, alumni, and fans. The school generating the most donations will receive a $1 million grant for student or community health, announced at the Big Ten Championship Game on Dec. 7. Participants receive a free one-month B1G+ streaming subscription and entry to win championship game tickets. The competition addresses declining younger donor numbers and aims to ensure a stable blood supply.
Abbott and Abbott Fund are responding to the devastation caused by Hurricanes Helene and Milton in the southeastern United States. Working with disaster relief partners like Feeding America, Direct Relief, Americares, and World Central Kitchen, they're providing aid to affected communities in Florida, Georgia, North Carolina, and Tennessee.
The company's proactive approach included pre-positioning 'disaster relief packs' with nutrition and medical products at food banks and health clinics. Additional donations of Ensure, PediaSure, Glucerna, Pedialyte, Similac, and diabetes care products have been made to meet immediate needs. Abbott Fund is also providing grants to support basic necessities and medical care in the aftermath of Hurricane Milton.
Abbott reported third-quarter 2024 results with sales of $10.6 billion, driven by strong underlying base business performance. Reported sales growth was 4.9%, with organic sales growth for the underlying base business at 8.2%, led by double-digit growth in Medical Devices. Abbott maintains its full-year 2024 organic sales growth guidance range of 9.5% to 10.0%, excluding COVID-19 testing-related sales. The company raised its full-year adjusted diluted EPS guidance to $4.64 to $4.70. Abbott's board authorized a new $7 billion share repurchase program. Notable developments include a partnership with Medtronic for continuous glucose monitoring, the U.S. launch of Lingo™, and completion of enrollment in the VOLT-AF IDE trial for the Volt™ Pulsed Field Ablation System.
Abbott (NYSE: ABT) announced significant progress in its pulsed field ablation (PFA) solutions for electrophysiology. The company completed enrollment ahead of schedule in the VOLT-AF IDE Study for the Volt™ PFA System and launched the global FOCALFLEX trial for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™. These studies advance two Abbott PFA catheters for treating atrial fibrillation (AFib).
Additionally, Abbott received FDA clearance for the Advisor™ HD Grid X Mapping Catheter, Sensor Enabled™, supporting mapping of PFA and radiofrequency ablation cases. The Volt PFA System pairs a balloon-in-basket catheter with Abbott's EnSite™ X EP System for improved heart mapping. The TactiFlex Duo Ablation Catheter offers both PFA and RF energy delivery with a flexible tip for precise targeting.
These advancements aim to overcome limitations of early-generation PFA systems and provide physicians with more options for treating AFib patients.
Abbott (NYSE: ABT) and the Big Ten Conference are launching 'The We Give Blood Drive', a first-of-its-kind nationwide blood donation competition among 18 Big Ten universities. The initiative aims to address the critical blood shortage in the U.S. and inspire younger donors. The competition runs from Sept. 26 to Dec. 6, 2024, with the winner announced at the Big Ten Championship Game on Dec. 7.
Key points:
- The school with the most blood donations wins a $1 million donation from Abbott for student or community health
- Participants receive a free one-month B1G+ streaming subscription and a chance to win tickets to the Big Ten Football Championship Game
- Donation totals will be tracked live at BigTen.Org/Abbott
- Abbott becomes the health sciences and diagnostics partner of the Big Ten Conference
Abbott (NYSE: ABT) has announced that it will release its third-quarter 2024 financial results on Wednesday, October 16, before the market opens. Following the announcement, the company will host a live webcast of its earnings conference call at 8 a.m. Central time (9 a.m. Eastern). Investors and interested parties can access the webcast through Abbott's Investor Relations website at www.abbottinvestor.com. For those unable to attend the live event, an archived edition of the call will be made available later the same day.
Abbott (NYSE: ABT) has declared its 403rd consecutive quarterly dividend of 55 cents per share. The dividend will be payable on Nov. 15, 2024, to shareholders of record as of Oct. 15, 2024. This announcement marks a significant milestone in Abbott's history of consistent dividend payments since 1924.
The company has demonstrated a remarkable track record of increasing its dividend payout for 52 consecutive years. This achievement has earned Abbott a place in the prestigious S&P 500 Dividend Aristocrats Index, which recognizes companies that have raised their dividends annually for at least 25 consecutive years.
Abbott's 2023 Global Sustainability Report highlights progress towards its 2030 Sustainability Plan goals, focusing on expanding health access and improving lives globally. Key achievements include:
1. Introducing the world's first dual-chamber leadless pacemaker system, expanding access to millions.
2. Partnering with mAbxience to increase access to biosimilar medicines in emerging markets.
3. Expanding emergency medicine reach to 1.3 million people in Tanzania.
4. Achieving a 7% reduction in Scope 1 and 2 carbon emissions.
5. Reducing overall water use by 3% and certifying four sites with Alliance for Water Stewardship.
6. Increasing sites with zero waste to landfill to 53 globally.
7. Doubling goals for creating development and job opportunities, including STEM programs for young people.
Abbott continues to integrate sustainability principles across its business to innovate for greater access and affordability in healthcare.
Abbott has launched Lingo™, a continuous glucose monitoring system available without prescription in the U.S. for consumers interested in improving overall health and wellness. Based on Abbott's FreeStyle Libre® technology, Lingo includes a biosensor worn on the arm for up to 14 days and a mobile app that provides real-time glucose data and personal coaching insights.
Lingo aims to help users build healthy habits, retrain their metabolism, and improve well-being by tracking glucose 24/7. The system offers features such as a glucose graph, Lingo Count™ metric, food and activity logging, personal insights, and challenges. Available for adults 18+ not on insulin, Lingo comes in three options: Learn (2 weeks), Build (4 weeks), and Transform (12 weeks), priced at $49, $89, and $249 respectively.
Abbott (NYSE: ABT) has initiated the TRANSCEND study, a pivotal clinical trial evaluating the use of its deep brain stimulation (DBS) system for treatment-resistant depression (TRD). The U.S. FDA granted Abbott Breakthrough Device designation for this research. TRD affects approximately 2.8 million Americans annually, with up to a third of major depressive disorder patients experiencing treatment resistance.
DBS works like a pacemaker, sending targeted electrical pulses to specific brain areas to relieve symptoms. Previous open-label studies have shown at least a 50% sustained improvement in depression symptoms for three out of four people over two to eight years. The TRANSCEND study aims to gather evidence on the impact of neurostimulation for TRD patients who have not responded to conventional treatments.